GS441524 1355149-45-9

1.Inquiries will be replied within 24 hours
2.We could supply various packages as you required
3.To protect the profit of our agents, price will not show on website, please send inquiries to get the price.
4.Fast delivery, goods arrive your office within 3 to 5 days
5.Please click "Inquiry" or "Email" below to get the price
GS441524 1
GS441524 1355149-45-9
Chemical Formula
GS441524 1355149-45-9
GS441524 1355149-45-9
Molecular Weight
GS441524 1355149-45-9
Storage and Stability
in stock

GS-441524现货 1355149-45-9猫传染性腹膜炎

研究小组分别使用了自然感染的猫腹膜巨噬细胞,以及人工感染(使用的是血清型2型的FIP病毒)的猫肾脏细胞(CRFK cell)进行了实验。实验显示,即便在低浓度的情况下,也能产生对FIP病毒繁殖抑制作用。






Feline coronavirus (FCoV) infection is very common in cats, and it is FCoV infection which can sometimes result in FIP. Infections with FCoV are usually asymptomatic but result in FIP in around 5-10% of cats1. Asymptomatic FCoV infection was previously believed to be confined to the intestinal tract, but we now know that healthy FCoV-infected cats can have systemic FCoV infection, albeit with lower FCoV viral loads than cats with FIP2-4. Why FCoVs result in FIP in some cats and not in the majority of FCoV-infected cats is the subject of much investigation. Viral factors are important. FCoVs have a spike (S) protein that binds to the host (feline) receptor, mediating host cell entry, and S gene mutations can result in amino acid substitutions in the transcribed S protein that influence the tropism of FCoV, and these are believed to be associated with the ability of FCoV replication to occur outside of the intestinal tract (i.e. in monocytes/macrophages) as systemic FCoV infection5, which is a prerequisite to the development of FIP. Other viral factors are also likely to be important for the subsequent development of FIP following systemic FCoV infection6. Host factors are also very likely to play an important part in FIP development; these include the immune response (e.g. T-lymphocyte depletion occurs in cats that develop FIP), the ability of monocytes to sustain FCoV replication, breed and genetics.
Objectives The aim of this study was to determine the safety and efficacy of the nucleoside analog GS-441524 for
cats suffering from various forms of naturally acquired feline infectious peritonitis (FIP).
Methods Cats ranged from 3.4–73 months of age (mean 13.6 months); 26 had effusive or dry-to-effusive FIP and five
had non-effusive disease. Cats with severe neurological and ocular FIP were not recruited. The group was started
on GS-441524 at a dosage of 2.0 mg/kg SC q24h for at least 12 weeks and increased when indicated to 4.0 mg/kg
SC q24h.
Results Four of the 31 cats that presented with severe disease died or were euthanized within 2–5 days and a
fifth cat after 26 days. The 26 remaining cats completed the planned 12 weeks or more of treatment. Eighteen of
these 26 cats remain healthy at the time of publication (OnlineFirst, February 2019) after one round of treatment,
while eight others suffered disease relapses within 3–84 days. Six of the relapses were non-neurological and two
neurological. Three of the eight relapsing cats were treated again at the same dosage, while five cats had the
dosage increased from 2.0 to 4.0 mg/kg q24h. The five cats treated a second time at the higher dosage, including
one with neurological disease, responded well and also remain healthy at the time of publication. However, one of
the three cats re-treated at the original lower dosage relapsed with neurological disease and was euthanized, while
the two remaining cats responded favorably but relapsed a second time. These two cats were successfully treated
a third time at the higher dosage, producing 25 long-time survivors. One of the 25 successfully treated cats was
subsequently euthanized due to presumably unrelated heart disease, while 24 remain healthy.
Conclusions and relevance GS-441524 was shown to be a safe and effective treatment for FIP. The optimum dosage was found to be 4.0 mg/kg SC q24h for at least 12 weeks.

Thank you for your company product support!

CAS No. :

Product Name :

Number :

Your name:



The company or laboratory name: